Why Is VIKING THERAPEUTICS (VKTX) Stock Moving Today?
By the Top Tier Newswire AI Desk · July 20, 2026 at 3:07 AM ET · reviewed against 7 wire stories
VIKING THERAPEUTICS (VKTX) is drawing unusual attention today. Our newswire has captured 7 stories on VKTX across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Why VKTX stock is moving today
VKTX stock is moving higher today, with optimism driven by Viking Therapeutics' progress in its weight-loss drug development. Analysts are expressing strong confidence in the company's pipeline, particularly its ongoing and upcoming phase 3 trials. The stock's recent performance reflects growing investor interest in its potential to disrupt the weight-loss market.
What Happened
Viking Therapeutics is currently advancing a new amylin-based weight-loss drug into human trials. The company recently initiated a phase 1 ascending dose trial of VK3019, an investigational dual amylin and calcitonin receptor agonist. This drug is designed to offer a novel approach to weight loss, potentially going beyond the mechanisms of GLP-1 therapies. Analysts are highlighting the drug's potential to deliver strong efficacy, which has contributed to the stock's upward movement. The company's efforts to expand its therapeutic options are seen as a key differentiator in a competitive market.
What The Data Shows
VKTX has a market cap of $4.3 billion and is currently unprofitable, with an earnings per share of -4.16 over the trailing twelve months. The stock has traded between $22.96 and $43.15 over the past 52 weeks. The stock's beta of 0.65 suggests it is less volatile than the broader market. Intraday volume has been elevated, indicating increased investor attention. The 30-day average sentiment score has improved from 60 to 66 over the last seven days, reflecting a growing positive outlook among market participants.
What To Watch
Investors should continue to monitor Viking Therapeutics' progress in its clinical trials, particularly the phase 1 trial of VK3019. Data from this trial is expected in the third quarter of 2026. Broader coverage and analyst commentary will also be important to track as the company advances its pipeline.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
VKTX · Jul 20 session (5-min) · -1.58% vs prior close · updated 8:50 PM ETAI sentiment, last 36h · averaged over 7 stories · 56/100 bullish
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
1h agoStocktwits NewsBULLISH 56Product/PR
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.
6h agoSeeking AlphaBULLISH 63Product/PR
Viking expects oral VK2735 Phase III start in fourth quarter as VANQUISH targets 78-week dosing
Viking Therapeutics (VKTX) Q2 2026 earnings call: VK2735 Phase III VANQUISH update, oral Phase III Q4 start, and near-term maintenance data—read now.
6h agoSeeking AlphaNEUTRAL 50Earnings
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call July 29, 2026 4:30 PM EDTCompany ParticipantsStephanie DiazBrian Lian - President, CEO &...
9h agoStocktwits NewsBULLISH 56Product/PR
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress
Viking has no approved drug products, and in the pre-revenue phase, investor attention centers almost entirely on clinical progress.
13h agoSEC 8-KNEUTRAL 50General
Viking Therapeutics, Inc. (VKTX) files 8-K
Filed: 2026-07-29 AccNo: 0001193125-26-323652 Size: 462 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
13h agoPR NewswireBULLISH 56Earnings
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- -- Phase 1 Study of Amylin...
1d agoYahoo FinanceBULLISH 58Analyst
Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case
The stock looks like a high-risk, high-reward play.
Frequently asked questions
Why is VKTX stock moving today?
VIKING THERAPEUTICS (VKTX) is drawing unusual attention today. Our newswire has captured 7 stories on VKTX across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100). The most recent driver: "VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t" (Stocktwits News).
Is VKTX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of VKTX coverage reads 56/100 over 7 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →